阿纳基纳
发病机制
类风湿性关节炎
医学
白细胞介素1受体拮抗剂
受体拮抗剂
关节炎
促炎细胞因子
免疫学
甲氨蝶呤
滑液
细胞因子
白细胞介素
炎症
疾病
敌手
内科学
受体
骨关节炎
病理
替代医学
出处
期刊:British journal of rheumatology
日期:2004-06-01
卷期号:43 (suppl_3): iii2-iii9
被引量:197
标识
DOI:10.1093/rheumatology/keh201
摘要
A significant body of experimental evidence has implicated the proinflammatory cytokine IL-1 in the pathogenesis of RA. For example, IL-1beta overexpression in rabbit knee joints causes arthritis with clinical and histological features characteristic of RA, whereas IL-1 deficiency is associated with reduced joint damage. In experimental models, IL-1 blockers, including IL-1 receptor antagonist (IL-1Ra), significantly reduce clinical and histological disease parameters. In RA patients, plasma and synovial fluid concentrations of IL-1 are elevated, and these correlate with various parameters of disease activity. The production of endogenous IL-1Ra, however, appears to be insufficient to balance these higher IL-1 levels. The efficacy of blocking IL-1 in patients with active RA has been established in controlled clinical trials of anakinra, a recombinant human IL-1Ra (r-metHuIL-1ra). When used alone or in combination with methotrexate, anakinra significantly reduces the clinical signs and symptoms of RA compared with placebo. Taken together, these results indicate that IL-1 plays an important role in the pathogenesis of RA.
科研通智能强力驱动
Strongly Powered by AbleSci AI